Home World News Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced... World News Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor By Ogkologos - October 12, 2026 397 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the evERA study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR After Losing His Mom To Breast Cancer, Man Founds ‘Not Just... September 5, 2019 如何在肺癌患病期间和之后维持性健康 November 23, 2022 Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not... April 8, 2025 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free. May 21, 2019 Load more HOT NEWS Dr Ian Walker on Smoking: ‘A political no-brainer’ Study Suggests Some Arthritis Drugs May Actually Stop the Spread of... Georgia Middle Schooler Donates All the Proceeds of Her Grand Champion... Opportunity and mentorship: Our new PhD programme aiming to open-up academia...
